论文部分内容阅读
目的探讨三维适形放疗联合金龙胶囊治疗原发性肝癌的临床疗效。方法52例原发性肝癌患者随机分为两组,单纯三维适形放疗组(对照组)和三维适形放疗联合金龙胶囊组(治疗组)各26例。观察两组治疗的近期疗效、临床受益反应率和不良反应。结果治疗组近期疗效76.9%,对照组57.6%,两组比较有显著性差异,P<0.05;治疗组临床受益率76.9%,对照组61.6%,两组比较有显著性差异,P<0.05。两组不良反应发生率比较,均无显著性差异,P>0.05。结论三维适形放疗联合金龙胶囊治疗原发性肝癌安全有效,值得推广。
Objective To investigate the clinical efficacy of three-dimensional conformal radiotherapy combined with Jinlong capsule in the treatment of primary liver cancer. Methods Fifty-two patients with primary liver cancer were randomly divided into two groups: 26 cases in each group treated with three-dimensional conformal radiotherapy alone (control group) and three-dimensional conformal radiotherapy combined with Jinlong Capsule group (treatment group). The two groups were observed the short-term efficacy of treatment, clinical benefit response rate and adverse reactions. Results The curative effect was 76.9% in the treatment group and 57.6% in the control group, with significant difference between the two groups (P <0.05). The clinical benefit rate in the treatment group was 76.9% and that in the control group was 61.6%. There was significant difference between the two groups (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions, P> 0.05. Conclusions Three-dimensional conformal radiotherapy and Jinlong Capsule are safe and effective in the treatment of primary hepatocellular carcinoma.